Meet Vu Truong, Founder and CEO of Aridis Pharmaceuticals (OTC: ARDS)

Aridis Pharmaceuticals (OTC: ARDS) is advancing multiple clinical stage monoclonal antibodies (mAbs) targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. Visit ARDSinfo.com to learn more. https://bit.ly/ARDSinfo RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. Aridis Pharmaceuticals, Inc. (ARDS) is a client of RedChip Companies, Inc. ARDS agreed to pay RedChip Companies, Inc. a $8,000 monthly cash fee, beginning in February 26th, 2022 and 5000 restricted common shares of ARDS stock for 6 months of RedChip investor awareness services. For full disclosure, visit RedChip.com/disclosures.